Summary of results
In this meta-analysis a statistically significant higher incidence rate of growth after endovascular therapy was found when compared to natural history studies. This difference remained statistically significant after adjustment for confounders and the sensitivity analyses showed similar results.
A potential theory: Inflammation and growth
Aneurysm growth seems to be linked to ongoing inflammation in the diseased wall.[28] Given that endovascular techniques also induce inflammation, this might underpin the effect we measured in our meta-analysis.
Endovascular techniques induce inflammation of the aneurysm wall in order to promote thrombosis and thus induce aneurysm healing and exclusion from circulation. Inflammation-inducing coils are thought to promote faster thrombosis.[27,29] Recently published studies show promising results when hydrogel coils are used.[5,26] However, the use of these bioactive coils has been a topic of great debate so far, as the long-term effects of the inflammation they induce is still unknown.[7] It is also unknown whether the inflammation which leads to growth and rupture is influenced in any way by the inflammation induced by endovascular treatment of aneurysms.
The inflammatory processes intrinsically happening inside the aneurysm wall as a reaction to the hemodynamic shear stress and circumferential wall stress are postulated to lead to growth and eventual rupture of the aneurysm.[28] Recent reports suggest an association between white blood cell count and increasing aneurysm size.[8] Inflammation and thrombosis also play an essential role in aneurysm healing after endovascular treatment. Several reports suggest the possibility of perifocal edema and white matter changes around aneurysms after endovascular treatment.[22,23,27] Histological studies on growing aneurysm remnants show similar inflammation in the vicinity of the coil mass and in the aneurysm wall.[25] There is a high likelihood that the two inflammatory processes influence each other, but the dynamic of this relationship is unknown. The recent growing use of flow diverters might obviate the risks associated with risk of growth after coiled aneurysms.
Differences between natural history studies and endovascular therapy studies
The most important difference observed between the natural history studies and the endovascular therapy studies is aneurysm size. There is an inevitable selection bias in patients that are included in natural history studies, both in terms of survivor bias due to confounding by indication.
There are many studies pointing out the fact that size of the aneurysm is one of the strongest risk factors for aneurysm growth.[1,2,6] The PHASES score, developed to predict the 5-year rupture risk, aids clinicians in decision-making for UIAs.[10] It also relies heavily on aneurysm size. Therefore, the two groups (natural history and endovascular treatment) are likely to have, at baseline, a different risk of growth. To make matters more complex, growth was measured on different imaging modalities, which might introduce a measurement bias. Most likely the very small aneurysms of the natural history group need to grow more than those from the endovascular treatment series in order for growth to be noticed. However, aneurysms in natural history series were followed for a longer period of time, allowing ample time to measure and record growth.
Most of the included endovascular intervention studies, especially the most recent ones (after 2005), report results and growth of aneurysms requiring stent-assisted coiling or another endovascular neck remodeling technique. They also report an over-represented population of basilar tip aneurysms. The aneurysms most often treated, AComs and PComs, are relatively under-represented. It is safe to assume there is an amount of reporting bias involved in which studies focused on aneurysm growth after endovascular therapy automatically report a selected population with a higher baseline risk of growth. The aIR should be interpreted in light of the fact that the medians of covariates were used, which inevitably leads to information loss and potential ecological bias.
Size is merely a surrogate marker of a process that cannot be characterized differently at this point. There are no reliable markers to determine in which aneurysm and in which patients this process is ongoing or halted. The underlying assumption that aneurysms under 7 mm rarely bleed is partially based on the inherent survivor bias population included in the natural history studies. Recent papers show a preponderance of small aneurysms with a theoretical low rupture risk in subarachnoid hemorrhage series.[19] These aneurysms have low PHASES scores and still make up the majority of the patients seen with subarachnoid hemorrhage.[20,12] Also, a high prevalence of small aneurysms leading to fatal subarachnoid hemorrhage in an autopsy series has been published.[17] Natural history studies likely underestimate the risk of hemorrhage, and so do scores based on them. The low rupture risk of small aneurysms is still a matter of debate.
The limitations of measuring and comparing the incidence of growth in unruptured aneurysms
A considerable amount of care in planning the study was given to the definition of the denominator of the incidence rate. We would have preferred to have the individual patient data of all studies available in order to conduct the present meta-analysis. Due to this data not being available and thus no possibility to calculate the aneurysm-years-at-risk, we settled for aneurysm-years.[24] The data presented in our study is likely the result of pooling together patients with a relatively low risk of growth and patients with relatively high risk of growth. While larger aneurysms are postulated to have a much higher risk of growth, most of the aneurysms in both groups were small. Some endovascular studies focused on smaller aneurysms.
Assuming there is a subset of patients in which aneurysm growth is triggered through endovascular treatment, these patients are now pooled together with low-risk patients. This subgroup is also impossible to identify using our data. These considerations force a cautious interpretation of our results. Nonetheless, we cannot exclude a significant influence of endovascular treatment on growth in certain aneurysms. Whether growing significant remnants after endovascular therapy can be equated with growing aneurysms and whether they have the same risk of bleeding is still a matter of debate. We only considered significant, growing recanalized aneurysms and growing remnants for comparison. All growing small neck remnants were excluded, otherwise the numbers would have been much higher. The 18-year follow-up of a subgroup of the International Subarachnoid Aneurysm Trial showed 3% of patients experiencing a subarachnoid haemorrhage from remnants of endovascularly treated aneurysms.[16]
We planned to perform sensitivity analyses including only studies reporting the outcomes of individual endovascular techniques (e.g. coiling, stent-assisted coiling, flow diverters) and compare them to the natural history. This was not possible as the studies did not report the outcomes of the individual techniques. The reporting overall was poor in terms of aneurysm growth, which led to us not being able to use all included studies for the aIR. Reporting should be improved in future studies.
We also planned to extract the packing density of coils, the remnant neck size and to relate this to growth, but unfortunately this data was also not available. It is conceivable that a neck remnant might provide fertile ground for unopposed inflammatory changes which might lead to further aneurysm expansion. An individual patient data meta-analysis would have solved many of the methodological issues we faced in this study and would have given more reliable and precise effect size estimates.
Future research focus
Aneurysm growth is used as a surrogate marker for aneurysm wall changes. However, the chain of events of aneurysm formation – growth – rupture has many unknown links which still need to be uncovered. More research is necessary in the field of inflammatory changes in the aneurysm wall in order to elucidate this process and identify patients at potential risk of inflammatory progression after endovascular treatment. Longitudinal vessel-wall imaging, together with blood biomarkers of inflammation could be used to this effect.